| 24小時(shí)熱門版塊排行榜 |
| 2 | 1/1 | 返回列表 |
| 查看: 1153 | 回復(fù): 1 | |||||||||||
[交流]
廣東醫(yī)科大學(xué)黃遵楠教授課題組招研究助理專業(yè)不限但生物信息優(yōu)先
|
廣東醫(yī)科大學(xué)黃遵楠教授擬招聘生物信息學(xué)或計(jì)算生物學(xué)研究方向的研究助理(本科、碩士畢業(yè)生皆可),化學(xué)、生物、醫(yī)藥等專業(yè)皆可,有意者請(qǐng)來(lái)信zn_huang@qq.com聯(lián)系。 黃遵楠,男,1972年出生,漢族,海歸博士,化學(xué)專業(yè)教授,博士生導(dǎo)師和博士后合作導(dǎo)師。曾在美國(guó)留學(xué)和工作12年,現(xiàn)為廣東醫(yī)科大學(xué)東莞科研中心副主任和中美腫瘤研究所副所長(zhǎng)。同時(shí)還兼任農(nóng)工黨廣東省委會(huì)聯(lián)絡(luò)專委會(huì)委員、東莞市委會(huì)科教經(jīng)濟(jì)專委會(huì)主任,二十個(gè)余個(gè)國(guó)際知名SCI期刊(包括JACS, IF=14.357)?妥鶊(zhí)行主編、主題研究主編、編委和審稿人,國(guó)家自然科學(xué)基金項(xiàng)目評(píng)議專家,廣東省自然科學(xué)基金、廣東特支計(jì)劃人才、廣東省教育廳高級(jí)職稱、廣東等四省科學(xué)技術(shù)獎(jiǎng)勵(lì)的評(píng)審專家,江蘇省科技咨詢專家,以及中國(guó)醫(yī)師協(xié)會(huì)臨床精準(zhǔn)醫(yī)療專業(yè)委員會(huì)第一屆委員會(huì)癌癥代謝與治療專業(yè)委員會(huì)委員,廣東省四個(gè)省級(jí)學(xué)會(huì)的理事或?qū)I(yè)委員會(huì)委員。是2013年廣東省“揚(yáng)帆計(jì)劃”引進(jìn)緊缺拔尖人才,2016年?yáng)|莞市第七屆優(yōu)秀科技工作者,2017年廣東省教育廳推薦“國(guó)家百千萬(wàn)工程人才”10名候選人之一。致力于計(jì)算生物和精準(zhǔn)藥物設(shè)計(jì),研究領(lǐng)域橫跨計(jì)算生物學(xué)、生物信息學(xué)、分子生物學(xué)、病理生理學(xué)、藥理學(xué)、中藥學(xué)以及臨床醫(yī)學(xué)。已主持國(guó)家和省部級(jí)課題7項(xiàng)(包括2項(xiàng)國(guó)家自然科學(xué)基金面上項(xiàng)目)。在國(guó)內(nèi)外期刊或?qū)V习l(fā)表學(xué)術(shù)論文66篇,SCI收錄論文的累積影響因子超過(guò)180。特別是2016年來(lái)已發(fā)表第一或通訊作者SCI論文22篇,累計(jì)影響因子70余分;主編Current Pharmaceutical Design和Current Medicinal Chemistry專刊各1期(現(xiàn)在已開(kāi)始新主編Frontier in Chemistry IF=4.155期刊一期);獲得國(guó)家發(fā)明專利一項(xiàng);教學(xué)科研成果受《人民日?qǐng)?bào)》和《科技日?qǐng)?bào)》等央媒體報(bào)道。 新聞報(bào)道:https://www.stdaily.com/cxzg80/guonei/2019-05/06/content_764146.shtml?from=singlemessage&isappinstalled=0 招聘要求: 1、勤奮踏實(shí)、有責(zé)任心、熱愛(ài)科學(xué)研究并具有團(tuán)隊(duì)精神; 2、具有良好的英語(yǔ)聽(tīng)說(shuō)讀寫能力,能夠獨(dú)立撰寫英文報(bào)告和論文。 廣東醫(yī)科大學(xué)東莞校區(qū)所在的松山湖科技園區(qū)綠化面積超過(guò)60%,環(huán)境優(yōu)美,空氣質(zhì)量高,氣候四季如春非常宜人,歡迎大家加入我們! 附2018年以來(lái)發(fā)表的Editorial和Article: 53. Binbin Li#, Nansong Xu#, Zheng Wan, Li Ma, Huahui Li, Weijie Cai, Xiumei Chen, Zunnan Huang* and Zhiwei He*, “Isobavachalcone exerts anti-proliferative and pro-apoptotic effects on human liver cancer cells by targeting the ERKs/RSK2 signaling pathway",Oncology Reports, 41:3355-3366, (2019) 52. Zunnan Huang* and Ruo-Xu Gu*, "Editorial: Development and Application of Computational Methods in Biology and Medicine", Current Medicinal Chemistry, 26, XXX-XXX (2019) 51. Juan Zeng*, Zunnan Huang*, "From Levinthal\\\'s Paradox to the Effects of Cell Environmental Perturbation on Protein Folding", Current Medicinal Chemistry, 26, XXX-XXX (2019) 50. Siqi Tang#, Bin Yao#,Na Li, Shuhuang Lin*, Zunnan Huang*, "The association of the currently available polymorphisms in dopamine beta-hydroxylase with three types of neurodegenerative diseases: from single locus to the combination of all accessible loci", Cellular Physiology and Biochemistry, 51(1), 411-428 (2018) 49. Yong Liu#, Jingan Chen#, Jieying Qian, Hao Lin, Ning Sun, Zunnan Huang*, "Evolutionary analysis and structural characterization of Aquilaria sinensis sesquiterpene synthase in agarwood formation: a computational study", Journal of Theoretical Biology, 456, 249-260 (2018) 48. Hongbin Huang$, Guigui Zhang$, Yuquan Zhou, Chenru Lin, Suling Chen, Yutong Lin, Shangkang Mai, Zunnan Huang*, "Reverse screening methods to search for protein targets of chemopreventive compounds", Frontiers in Chemistry, 6: 138 (2018) 47. Qingcheng Du$, Guanming Jiang$, Silu Li, Yong Liu*, Zunnan Huang*, "Docetaxel increases the risk of severe infections in the treatment of non-small cell lung cancer: a meta-analysis", Oncoscience, 5(7-8):220-238 (2018) 46. Shuhuang Lin$, Xu Liu$, Bin Yao, Zunnan Huang*, "Controlling for confounding factors and revealing their interactions in genetic association meta-analyses: a computing method and application for stratification analyses", Oncotarget, 9(15):12125-12316 (2018) 45. Xiangning Zhang$*, Song-Jun Shao$, Jia-Hui Zhou, Xiao-Wu Li, Biying Zheng, Zunnan Huang*, Zhiwei He*, "Tumor suppressor BLU exerts growth inhibition by blocking ERK signaling and disrupting cell progression through RAS pathway interference", International Journal of Clinical and Experimental Pathology, 11(1): 158-168 (2018) [ 來(lái)自版塊群 廣東 ] |
| 2 | 1/1 | 返回列表 |
| 最具人氣熱帖推薦 [查看全部] | 作者 | 回/看 | 最后發(fā)表 | |
|---|---|---|---|---|
|
[考研] 理學(xué)07化學(xué) 303求調(diào)劑 +4 | 睿08 2026-03-27 | 4/200 |
|
|---|---|---|---|---|
|
[考研] 哈爾濱工業(yè)大學(xué)材料與化工專碩378求調(diào)劑 +3 | 塔比烏斯 2026-03-30 | 3/150 |
|
|
[考研] 學(xué)碩274求調(diào)劑 +10 | Li李魚(yú) 2026-03-26 | 10/500 |
|
|
[考研]
|
鐘llll 2026-03-26 | 5/250 |
|
|
[考研] 295材料工程專碩求調(diào)劑 +10 | 1428151015 2026-03-27 | 10/500 |
|
|
[考研] 071010 323 分求調(diào)劑 +3 | Baekzhy 2026-03-27 | 3/150 |
|
|
[考研] 283求調(diào)劑(080500) +14 | A child 2026-03-27 | 14/700 |
|
|
[考研] 085600,材料與化工321分求調(diào)劑 +10 | 大饞小子 2026-03-28 | 10/500 |
|
|
[考研] 290求調(diào)劑 +3 | dfffsar 2026-03-29 | 3/150 |
|
|
[考研] 321求調(diào)劑 +7 | 璞玉~~ 2026-03-25 | 8/400 |
|
|
[考研]
|
y7czhao 2026-03-26 | 10/500 |
|
|
[考研] 304求調(diào)劑 +6 | 曼殊2266 2026-03-27 | 6/300 |
|
|
[考研] 085405 考的11408求各位老師帶走 +3 | Qiu學(xué)ing 2026-03-28 | 3/150 |
|
|
[考研] 張芳銘-中國(guó)農(nóng)業(yè)大學(xué)-環(huán)境工程專碩-298 +4 | 手機(jī)用戶 2026-03-26 | 4/200 |
|
|
[考研] 275求調(diào)劑 +10 | jjjjjjjjjjl 2026-03-27 | 10/500 |
|
|
[考研]
|
18419759900 2026-03-25 | 8/400 |
|
|
[考研] 安徽大學(xué)專碩生物與醫(yī)藥專業(yè)(086000)324分,英語(yǔ)已過(guò)四六級(jí),六級(jí)521,求調(diào)劑 +4 | 美味可樂(lè)雞翅 2026-03-26 | 4/200 |
|
|
[考研] 打過(guò)很多競(jìng)賽,085406控制工程300分,求調(diào)劑 +3 | askeladz 2026-03-26 | 3/150 |
|
|
[考研] 347求調(diào)劑 +4 | L when 2026-03-25 | 4/200 |
|
|
[考研] 材料專碩331求調(diào)劑 +4 | 鮮當(dāng)牛 2026-03-24 | 4/200 |
|